Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Unknown 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Conditions

Urinary Bladder Neoplasms 1Ureteral Neoplasms 1Rare Diseases 1Paraproteinemias 1Neuromyelitis Optica 1Neurologic Manifestations 1Nervous System Diseases 1Neoplasms, Plasma Cell 1Myelitis, Transverse 1Myasthenia Gravis 1Multiple Sclerosis 1Multiple Myeloma 1Mental Disorders 1Kidney Diseases 1Hematologic Diseases 1Encephalomyelitis, Acute Disseminated 1Diffuse Cerebral Sclerosis of Schilder 1Autoimmune Diseases 1Acute Kidney Injury 1

Interventions

Bevacizumab 4Temozolomide 3Irinotecan 3Sorafenib 2Radiosurgery 2pembrolizumab 1ibrutinib 1Vorinostat 1Valproic Acid 1Transcranial Magnetic Stimulation 1Therapeutics 1Thalidomide 1Standard of Care 1Sildenafil Citrate 1Radiotherapy 1Pliability 1Plasma Exchange 1Palliative Care 1Nivolumab 1Morphine 1Methadone 1Lenalidomide 1Immunoglobulins 1Exercise 1Equipment and Supplies 1Clomipramine 1Carboplatin 1Bendamustine Hydrochloride 1Atorvastatin 1Amifampridine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Interventional × Neurologic Manifestations × Plasma Exchange × Clear all
NCT00004645 2005-06-24

Phase III Randomized, Double-Blind, Sham-Controlled Study of Plasma Exchange for Acute Severe Attacks of Inflammatory Demyelinating Disease Refractory to Intravenous Methylprednisolone

Office of Rare Diseases (ORD)

Phase 3 Unknown
22 enrolled

Mental Disorders, Diffuse Cerebral Sclerosis of Schilder, Encephalomyelitis, Acute Disseminated, Multiple Sclerosis, Myelitis, Transverse, Neurologic Manifestations, Neuromyelitis Optica, Rare Diseases

Data powered by HemOnc (CC BY 4.0) Colophon âš¡